GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure
Journal of Urologic Oncology · 31.07.2026 · 24 (2) · 109-118
DOI: 10.22465/juo.265200340017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Urologic Oncology, erschienen am 31.07.2026. Verfasst von Ja Yoon Heo und 15 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yonsei University College of Medicine.
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the prognostic significance of GATA6 alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel after androgen receptor pathway inhibitor (ARPI) failure.Materials and Methods: In this retrospective exploratory cohort study, patients with mCRPC who received docetaxel after prior ARPI therapy were included. Clinical and genomic data were reviewed, and Cox proportional hazards models were used to evaluate the prognostic impact of genomic alterations present in ≥5% of the cohort.
Results
A total of 90 patients were analyzed (median age, 70.5 years; median follow-up, 17.7 months). GATA6 alteration was identified in 5 patients (5.6% of the cohort). In the gene-only analysis, GATA6 alteration was associated with shorter radiographic progression-free survival (rPFS) in both univariate (hazard ratio [HR], 7.44; 95% confidence interval [CI], 2.72–20.33; p
Förderung
- Yonsei University College of Medicine
Zitieren
APA
Heo, J. Y., Lee, C., Shin, H., Cho, S., Beom, S. H., Choi, Y., Han, W. K., Ham, W. S., Jang, W. S., Han, H., Lee, J., Heo, J. E., Kim, S., Jung, M., Kim, C. G., & Shin, S. J. (2026). GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure. Journal of Urologic Oncology, 24(2), 109-118. https://doi.org/10.22465/juo.265200340017
Vancouver
Heo JY, Lee C, Shin H, Cho S, Beom SH, Choi Y, et al. GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure. Journal of Urologic Oncology. 2026;24(2):109-118. doi:10.22465/juo.265200340017
BibTeX
@article{Heo2026,
author = {Heo, Ja Yoon and Lee, Chung and Shin, Heesun and Cho, Sungmin and Beom, Seung Hoon and Choi, Young-Deuk and Han, Woong Kyu and Ham, Won Sik and Jang, Won Sik and Han, Hyunho and Lee, Jongsoo and Heo, Ji Eun and Kim, Sangwoo and Jung, Minsun and Kim, Chang Gon and Shin, Sang Joon},
title = {GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure},
journal = {Journal of Urologic Oncology},
year = {2026},
volume = {24},
number = {2},
pages = {109--118},
doi = {10.22465/juo.265200340017}
}
EUVIMED